Trade bluebird bio, Inc. - BLUE CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.20 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023374% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001151% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 9.04 |
| Open | 9.27 |
| 1-Year Change | 283.06% |
| Day's Range | 7.99 - 9.59 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 20, 2024 | 8.47 | -0.17 | -1.97% | 8.64 | 9.68 | 7.74 |
| Dec 19, 2024 | 9.04 | 0.55 | 6.48% | 8.49 | 9.54 | 8.00 |
| Dec 18, 2024 | 8.31 | -0.52 | -5.89% | 8.83 | 9.63 | 7.99 |
| Dec 17, 2024 | 8.79 | 1.09 | 14.16% | 7.70 | 9.39 | 7.32 |
| Dec 16, 2024 | 7.71 | 1.73 | 28.93% | 5.98 | 7.91 | 5.90 |
| Dec 13, 2024 | 6.29 | -1.11 | -15.00% | 7.40 | 7.40 | 6.18 |
| Dec 12, 2024 | 0.37 | 0.00 | 0.00% | 0.37 | 0.39 | 0.36 |
| Dec 11, 2024 | 7.40 | -0.40 | -5.13% | 7.80 | 8.00 | 7.40 |
| Dec 10, 2024 | 8.00 | -0.40 | -4.76% | 8.40 | 8.60 | 7.60 |
| Dec 9, 2024 | 8.60 | -1.20 | -12.24% | 9.80 | 9.80 | 8.20 |
| Dec 6, 2024 | 8.80 | 0.80 | 10.00% | 8.00 | 8.80 | 8.00 |
| Dec 5, 2024 | 8.40 | -1.00 | -10.64% | 9.40 | 10.80 | 7.80 |
| Dec 4, 2024 | 13.80 | 7.00 | 102.94% | 6.80 | 15.00 | 6.80 |
| Dec 3, 2024 | 6.80 | -1.20 | -15.00% | 8.00 | 8.00 | 6.80 |
| Dec 2, 2024 | 8.00 | 0.20 | 2.56% | 7.80 | 8.40 | 7.60 |
| Nov 29, 2024 | 7.80 | 0.80 | 11.43% | 7.00 | 7.80 | 7.00 |
| Nov 27, 2024 | 7.00 | 0.00 | 0.00% | 7.00 | 7.20 | 6.80 |
| Nov 26, 2024 | 7.00 | 0.00 | 0.00% | 7.00 | 7.00 | 6.60 |
| Nov 25, 2024 | 6.80 | 0.00 | 0.00% | 6.80 | 7.80 | 6.80 |
| Nov 22, 2024 | 6.60 | 1.00 | 17.86% | 5.60 | 6.80 | 5.60 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Bluebird Company profile
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease. The company's lead product candidates in oncology include bb2121 and bb21217, which are anti- B-cell maturation antigens in Phase I clinical trials for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. It also has collaborations with Medigene AG for the research and development of T cell receptor product candidates directed against antigens for the treatment of cancer indications; and TC BioPharm Limited to research and develop gamma delta chimeric antigen receptor modified T cell product candidates for cancer immunotherapy, as well as a partnership agreement with Celgene European Investment Company LLC. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.| Industry: | Bio Therapeutic Drugs |
455 Grand Union Boulevard
SOMERVILLE
MASSACHUSETTS 02145
US
News
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
22:39, 12 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com